SIGA Technologies Inc(SIGA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.04 | Insider Own | 42.83% | Shs Outstand | 71.8M | Perf Week | -6.19% |
| Market Cap | 0.22B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 41.1M | Perf Month | 5.57% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 48.82% | Short Float | 8.64% | Perf Quarter | -29.7% |
| Income | -0.00B | P/S | 4.06 | EPS this Y | - | Inst Trans | 0.71% | Short Ratio | 4.92 | Perf Half Y | -37.38% |
| Sales | 0.05B | P/B | 1.32 | EPS next 5Y | - | ROA | -1.36% | Short Interest | 3.55M | Perf YTD | -43.94% |
| Book/sh | 2.3 | P/C | 1.85 | EPS past 3/5Y | -10.75% -14.51% | ROE | -1.49% | 52W High | -63.75% ($8.36) | Perf Year | -62.24% |
| Cash/sh | 1.64 | P/FCF | - | Sales past 3/5Y | -5.13% -5.42% | ROIC | -1.69% | 52W Low | 7.07% ($2.83) | Perf 3Y | -6.65% |
| Dividend Est. | $0.6 (19.8%) | EV/EBITDA | - | EPS Y/Y TTM | -103.41% | Gross Margin | 54.35% | Volatility(W/M) | 4.95% 4.59% | Perf 5Y | -28.04% |
| Dividend TTM | - | EV/Sales | 1.87 | Sales Y/Y TTM | -70.13% | Oper. Margin | -20.76% | ATR (14) | 0.14 | Perf 10Y | 94.9% |
| Dividend Ex-Date | 2026/4/7 | Quick Ratio | 16.48 | EPS Q/Q | -64.94% | Profit Margin | -5.19% | RSI (14) | 43.25 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 21.72 | Sales Q/Q | -49.45% | SMA20 | -1.7% ($3.08) | Beta | 1.06 | Target Price | $11.57 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -6.19% ($3.23) | Rel Volume | 0.63 | Prev Close | $3.02 |
| Employees | 49 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -34.14% ($4.6) | Avg Volume(3M) | 0.72M | Price | $3.03 |
| IPO | 1997/9/9 | Option/Short | Yes/Yes | Trades | 2389 | Volume | 453,288 | Change | 0.33% |
Company
SIGA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
SIGA Technologies is a U.S. biodefense company developing antiviral treatments targeting high-risk pathogens such as smallpox and mpox (monkeypox). Centered on its core product TPOXX—an antiviral therapy available in both oral and intravenous formulations—the company operates a public health security-focused business model, generating revenue through U.S. government stockpiling contracts and procurement agreements with foreign governments.
Over the past 1 year, on the lower side
64% below its 1-year high.
SIGA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Opinions on the outlook are split
Positive and negative signals are mixed
Tap to view numbers
Holding long would have lost money
Would have changed by -6.7% if bought 5 years ago.
Tap to view numbers
Dividends are paid consistently
Pays 19.80% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 48.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
ABLS 0.01%
DEEP 0.01%
MYLD 0.01%
QQQS 0.00%
SVAL 0.00%It ranks #4 in the industry
Based on market cap of $218M.
SIGA $218M PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is SIGA?
SIGA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SIGA?
The market cap of SIGA is approximately $218M, ranking 4,054 within its sector.
Does SIGA pay dividends?
SIGA has a dividend yield of approximately 19.80%, with an annual dividend of $0.60.
What is the 52-week high and low for SIGA?
SIGA has recorded a 52-week high of $8.36 and a low of $2.83.
